Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2015

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    EP04.01 - Global Health, Health Services Research, and Health Economics - Cost Issues

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Global Health, Health Services Research, and Health Economics - Cost Issues
    • +

      EP04.01-010 - Addressing Barriers to Lung Cancer Care for Diverse Populations through Patient Navigation: The University of Miami Experience

      Presenter: Estelamari Rodriguez

      • Abstract

      Loading...

  • +

    EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      EP08.01-090 - Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront.

      Presenter: Teresa Gorria

      • Abstract

      Loading...

    • +

      EP08.01-091 - Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront

      Presenter: Teresa Gorria

      • Abstract

      Loading...

  • +

    EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      EP08.02-041 - NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study

      Presenter: Alexander Drilon

      • Abstract

      Loading...

    • +

      EP08.02-042 - EGFR-TKI +/- Antiangiogenics for EGFR-mutated Advanced NSCLC

      Presenter: Laercio Lopes DaSilva

      • Abstract

      Loading...

  • +

    EP16.03 - Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Tumor Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
    • +

      EP16.03-021 - Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)

      Presenter: Luis Raez, MD, FACP, FCCP

      • Abstract

      Loading...

  • +

    OA06 - Impact of COVID-19 on Cancer Management and Protection from Vaccines

    • 11:00 - 12:10
    • 8/08/2022
    • Location: Lehar 1
    • Not for CME Credit
    • Type: Oral
    • Track: Management of Lung Cancer in the Era of COVID-19
    • +

      OA06.06 - Impact of Systemic Anti-cancer Treatments on Outcomes of COVID-19 in Patients with Thoracic Cancers: CCC19 Registry Analysis

      11:32 - 11:42  |  Presenter: Amit Kulkarni

      • Abstract

      Loading...

  • +

    OA15 - Patient Selection in Advanced NSCLC Immunotherapy

    • 14:30 - 15:30
    • 8/09/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      OA15.06 - Pooled Analysis of Outcomes With Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer

      15:02 - 15:12  |  Presenter: Delvys Rodriguez-Abreu

      • Abstract

      Loading...